Marker Therapeutics (MRKR) Amortizatization of Intangibles (2014 - 2021)
Marker Therapeutics (MRKR) posted quarterly Amortizatization of Intangibles of $253726.0 for Q3 2021, up 5.47% year-over-year from $240557.0 in Q3 2020, and little changed quarter-over-quarter from $252606.0 in Q2 2021.
Marker Therapeutics (MRKR) Amortizatization of Intangibles (2014 - 2021) Analysis & Trends
Marker Therapeutics (MRKR) has reported Amortizatization of Intangibles for 4 consecutive years, with $253726.0 the latest figure, recorded in Q3 2021.
- In Q3 2021, Amortizatization of Intangibles rose 5.47% year-over-year to $253726.0; the TTM figure through Sep 2021 stood at $1.0 million (up 163.09% YoY), while the FY2020 annual figure was $590039.0, up 225.16% from the prior year.
- Amortizatization of Intangibles steadied at $253726.0 in Q3 2021 per MRKR's latest filing, from $252606.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $253726.0 in Q3 2021 and bottomed at $44211.0 in Q1 2019.
- Historically, Amortizatization of Intangibles has averaged $139041.5 across 3 years, with a median of $49612.0 in 2020.
- Annual changes were most pronounced in 2020 — Amortizatization of Intangibles soared 442.56% — and 2021, when it climbed 5.47%.
- Marker Therapeutics' Amortizatization of Intangibles stood at $46540.0 in 2019, then jumped by 442.56% to $252509.0 in 2020, then gained by 0.48% to $253726.0 in 2021.
- Business Quant data shows MRKR's Amortizatization of Intangibles at $253726.0 in Q3 2021, $252606.0 in Q2 2021, and $251626.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 253,726.00 |
| Sep 30, 2021 | 253,726.00 |
| Jun 30, 2021 | 252,606.00 |
| Jun 30, 2021 | 252,606.00 |
| Mar 31, 2021 | 251,626.00 |
| Mar 31, 2021 | 251,626.00 |
| Dec 31, 2020 | 252,509.00 |
| Dec 31, 2020 | 252,509.00 |
| Sep 30, 2020 | 240,557.00 |
| Sep 30, 2020 | 240,557.00 |
| Jun 30, 2020 | 49,612.00 |
| Jun 30, 2020 | 49,612.00 |
| Mar 31, 2020 | 47,361.00 |
| Mar 31, 2020 | 47,361.00 |
| Dec 31, 2019 | 46,540.00 |
| Dec 31, 2019 | 46,540.00 |
| Sep 30, 2019 | 45,741.00 |
| Sep 30, 2019 | 45,741.00 |
| Jun 30, 2019 | 44,967.00 |
| Jun 30, 2019 | 44,967.00 |